Trust serves as the invisible currency of healthcare. When a sick person walks into a clinic, they offer their body and their vulnerability in exchange for expert care. They believe the person in the white coat operates solely to make them well. But in many parts of the world, that transaction has been corrupted. The diagnosis you receive might not be based on what ails you, but on which pharmaceutical representative visited the doctor that morning.
Mishal Khan has spent her career dragging these shadowy exchanges into the light. A Professor of Health Policy and Systems at the London School of Hygiene and Tropical Medicine (LSHTM), Khan does not merely study health systems; she dismantles the illusions surrounding them. Her work exposes a harsh reality where commercial interests cannibalize patient welfare, leaving the world’s most vulnerable populations to pay the price.
Khan operates with a specific type of bravery required to challenge the heavyweights of the medical establishment. She identifies the rot within the global health governance system. While others discuss policy in abstract terms, Khan orchestrates ambitious investigations that reveal exactly how money changes hands behind closed doors. Her research into the commercialization of healthcare reveals that when profit dictates policy, patients become commodities.
The High Cost Of Hidden Incentives
Private interests often overtake public duty in low- and middle-income nations. Khan spearheaded a groundbreaking investigation in Pakistan utilizing “standardized patients”—actors trained to present specific symptoms to doctors. This method allowed her team to observe the raw, unpolished reality of medical consultations. The findings were damning. They uncovered widespread practices in which medical decisions were influenced by financial kickbacks rather than clinical necessity. Doctors prescribed unnecessary drugs or ordered useless tests because pharmaceutical companies incentivized them to do so.
This is not a localized issue; it is a systemic failure that bleeds across borders. Khan argues that ignoring these informal markets renders any high-level health policy useless. You can build hospitals and train staff, but if the underlying incentive structure rewards corruption, health outcomes will stagnate.
“We cannot simply pour money into broken vessels and expect the water to stay clean,” Khan asserts. “When we allow commercial incentives to steer the prescription pad, we are not treating patients. We are processing customers for an industry that values revenue over recovery.”
Her analysis cuts through the jargon that often obscures these failures. The pharmaceutical industry wields immense power, shaping norms and effectively purchasing influence. Khan challenges the established order by quantifying exactly how much this influence costs the average citizen. Her data provides the ammunition reformers need to demand accountability. She proves that corruption is not a vague cultural artifact but a calculated mechanism of extraction.
Shattering The Ivory Tower
Khan’s perspective is sharpened by her own trajectory through the rigid academic hierarchies. She broke barriers early, entering Cambridge University as an “outsider” from a background under-represented in the elite halls of British education. She secured a double first-class degree and, at just 24, published a randomized controlled trial in The Lancet. This is a feat that most researchers strive for over the course of decades. By the age of 40, she had risen to the rank of full professor at LSHTM.
Yet, her ascent did not silence her. It amplified her demand for justice. Khan has become a leading voice on decolonization and racial equity in public health, speaking out when the Black Lives Matter movement forced a global reckoning. She understands that the power dynamics limiting women and ethnic minorities in academia mirror the dynamics suppressing lower-income countries on the global stage.
She served on the team overseeing an Independent Review of Racism at her institution, refusing to let her peers’ discomfort halt the necessary work. This willingness to critique the hand that feeds is rare. Most professionals play it safe to protect their grants and tenure. Khan wagers her reputation on the belief that truth is more valuable than comfort.
“We have to ask who sits at the table when decisions are made,” Khan notes. “If the people designing the solutions have never felt the problem, their answers will always be theoretical. We need to strip away the unjust hierarchies that keep local experts from leading the charge in their own countries.”
The Demand For Accountability
We stand at a precipice regarding global health funding. Aid budgets are shrinking, and the scrutiny on how every dollar is spent has intensified. Khan’s work offers a roadmap for this lean era. She insists that funders must look beyond the glossy reports and confront the messy reality of implementation. Real progress requires identifying the political blocks and the financial leaks that drain resources before they reach those in need.
Her research signals a departure from the “white savior” complex that has plagued international aid for nearly a century. Instead of importing solutions from the West, Khan advocates for systems that empower local governance to reject predatory commercial practices. She advocates a model in which lower-income countries take control of their health priorities, rather than being dictated to by foreign donors or multinational corporations.
The stakes could not be higher. If we fail to address the commercial determinants of health, the gap between the rich and the sick will widen until it swallows entire health systems. Mishal Khan provides the evidence we need to stop that slide. She forces us to confront the uncomfortable truths about why we fail to heal the world. Now that we have seen the data, the only question remains: do we have the courage to act on it?
